GSK plc (GSK)

GB — Healthcare Sector
Peers: NVS  AZN  RHHBY  BMY  AMGN  MRK  ABBV  GILD  JNJ  SNY  BIIB 

Automate Your Wheel Strategy on GSK

With Tiblio's Option Bot, you can configure your own wheel strategy including GSK - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol GSK
  • Rev/Share 7.7277
  • Book/Share 3.3466
  • PB 4.028
  • Debt/Equity 0.0
  • CurrentRatio 0.8682
  • ROIC 0.1098

 

  • MktCap 57236777509.0584
  • FreeCF/Share 0.8929
  • PFCF 15.7114
  • PE 18.0857
  • Debt/Assets 0.0
  • DivYield 0.042
  • ROE 0.2244

 

  • Rating B+
  • Score 3
  • Recommendation Neutral
  • P/E Score 2
  • DCF Score 4
  • P/B Score 2
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Downgrade GSK Berenberg Buy Hold -- -- June 3, 2025
Initiation GSK Exane BNP Paribas -- Neutral -- $35.25 April 15, 2025
Initiation GSK Morgan Stanley -- Equal Weight -- -- Feb. 12, 2025

News

Levi & Korsinsky Reminds GSK plc Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7, 2025 - GSK
GSK
Published: March 19, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / March 19, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=137181&wire=1 or contact Joseph E. Levi, Esq.

Read More
image for news Levi & Korsinsky Reminds GSK plc Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7, 2025 - GSK
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in GSK plc of Class Action Lawsuit and Upcoming Deadlines - GSK
GSK
Published: March 19, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / March 19, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against GSK plc ("GSK" or the "Company") (NYSE:GSK). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.

Read More
image for news INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in GSK plc of Class Action Lawsuit and Upcoming Deadlines - GSK
GSK LAWSUIT ALERT: Levi & Korsinsky Notifies GSK plc Investors of a Class Action Lawsuit and Upcoming Deadline
GSK
Published: March 18, 2025 by: GlobeNewsWire
Sentiment: Neutral

NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in GSK plc ("GSK" or the "Company") (NYSE: GSK) of a class action securities lawsuit.

Read More
image for news GSK LAWSUIT ALERT: Levi & Korsinsky Notifies GSK plc Investors of a Class Action Lawsuit and Upcoming Deadline
Investors in GSK plc Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights - GSK
GSK
Published: March 18, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / March 18, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=136884&wire=1 or contact Joseph E. Levi, Esq.

Read More
image for news Investors in GSK plc Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights - GSK
GSK plc. (GSK) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
GSK
Published: March 18, 2025 by: PRNewsWire
Sentiment: Neutral

BENSALEM, Pa. , March 18, 2025 /PRNewswire/ -- The Law Offices of Howard G.

Read More
image for news GSK plc. (GSK) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
ROSEN, A TOP RANKED LAW FIRM, Encourages GSK plc Investors to Secure Counsel Before Important Deadline in Securities Class Action - GSK
GSK
Published: March 18, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / March 18, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Receipts ("ADRs") of GSK plc (NYSE:GSK) between February 5, 2020 and August 14, 2022, both dates inclusive (the "Class Period"), of the important April 7, 2025 lead plaintiff deadline. SO WHAT: If you purchased GSK ADRs during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Read More
image for news ROSEN, A TOP RANKED LAW FIRM, Encourages GSK plc Investors to Secure Counsel Before Important Deadline in Securities Class Action - GSK
The Gross Law Firm Reminds GSK plc Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7, 2025 – GSK
GSK
Published: March 17, 2025 by: GlobeNewsWire
Sentiment: Neutral

NEW YORK, March 17, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of GSK plc (NYSE: GSK).

Read More
image for news The Gross Law Firm Reminds GSK plc Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7, 2025 – GSK
Class Action Filed Against GSK plc (GSK) Seeking Recovery for Investors - Contact Levi & Korsinsky
GSK
Published: March 17, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / March 17, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=136684&wire=1 or contact Joseph E. Levi, Esq.

Read More
image for news Class Action Filed Against GSK plc (GSK) Seeking Recovery for Investors - Contact Levi & Korsinsky
Lost Money on GSK plc (GSK)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
GSK
Published: March 17, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / March 17, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=136646&wire=1 or contact Joseph E. Levi, Esq.

Read More
image for news Lost Money on GSK plc (GSK)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages GSK plc Investors to Secure Counsel Before Important Deadline in Securities Class Action – GSK
GSK
Published: March 14, 2025 by: GlobeNewsWire
Sentiment: Neutral

NEW YORK, March 14, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Receipts (“ADRs”) of GSK plc (NYSE: GSK) between February 5, 2020 and August 14, 2022, both dates inclusive (the “Class Period”), of the important April 7, 2025 lead plaintiff deadline.

Read More
image for news ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages GSK plc Investors to Secure Counsel Before Important Deadline in Securities Class Action – GSK
Why GSK (GSK) is a Top Momentum Stock for the Long-Term
GSK
Published: March 14, 2025 by: Zacks Investment Research
Sentiment: Positive

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Read More
image for news Why GSK (GSK) is a Top Momentum Stock for the Long-Term
Levi & Korsinsky Reminds GSK Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7, 2025 - GSK
GSK
Published: March 13, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / March 13, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=135815&wire=1 or contact Joseph E. Levi, Esq.

Read More
image for news Levi & Korsinsky Reminds GSK Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7, 2025 - GSK
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in GSK plc of Class Action Lawsuit and Upcoming Deadlines - GSK
GSK
Published: March 13, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / March 13, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against GSK plc ("GSK" or the "Company") (NYSE:GSK). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.

Read More
image for news INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in GSK plc of Class Action Lawsuit and Upcoming Deadlines - GSK
GSK LAWSUIT ALERT: Levi & Korsinsky Notifies GSK plc Investors of a Class Action Lawsuit and Upcoming Deadline
GSK
Published: March 12, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / March 12, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=135563&wire=1 or contact Joseph E. Levi, Esq.

Read More
image for news GSK LAWSUIT ALERT: Levi & Korsinsky Notifies GSK plc Investors of a Class Action Lawsuit and Upcoming Deadline
GSK plc Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights - GSK
GSK
Published: March 11, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / March 11, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=135280&wire=1 or contact Joseph E. Levi, Esq.

Read More
image for news GSK plc Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights - GSK
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in GSK plc of Class Action Lawsuit and Upcoming Deadlines - GSK
GSK
Published: March 11, 2025 by: PRNewsWire
Sentiment: Neutral

NEW YORK , March 11, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against GSK plc ("GSK" or the "Company") (NYSE: GSK). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.

Read More
image for news INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in GSK plc of Class Action Lawsuit and Upcoming Deadlines - GSK
ROSEN, A NATIONAL INVESTOR RIGHTS FIRM, Encourages GSK plc Investors to Secure Counsel Before Important Deadline in Securities Class Action - GSK
GSK
Published: March 10, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / March 10, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Receipts ("ADRs") of GSK plc (NYSE:GSK) between February 5, 2020 and August 14, 2022, both dates inclusive (the "Class Period"), of the important April 7, 2025 lead plaintiff deadline. SO WHAT: If you purchased GSK ADRs during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Read More
image for news ROSEN, A NATIONAL INVESTOR RIGHTS FIRM, Encourages GSK plc Investors to Secure Counsel Before Important Deadline in Securities Class Action - GSK
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of GSK plc (GSK) Shareholders
GSK
Published: March 10, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / March 10, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=135038&wire=1 or contact Joseph E. Levi, Esq.

Read More
image for news Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of GSK plc (GSK) Shareholders
Investors who lost money on GSK plc (GSK) should contact Levi & Korsinsky about pending Class Action - GSK
GSK
Published: March 10, 2025 by: GlobeNewsWire
Sentiment: Neutral

NEW YORK, March 10, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in GSK plc ("GSK" or the "Company") (NYSE: GSK) of a class action securities lawsuit.

Read More
image for news Investors who lost money on GSK plc (GSK) should contact Levi & Korsinsky about pending Class Action - GSK
Lost Money on GSK plc(GSK)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
GSK
Published: March 07, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / March 7, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=134677&wire=1 or contact Joseph E. Levi, Esq.

Read More
image for news Lost Money on GSK plc(GSK)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
ROSEN, A LEADING LAW FIRM, Encourages GSK plc Investors to Secure Counsel Before Important Deadline in Securities Class Action - GSK
GSK
Published: March 07, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / March 7, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Receipts ("ADRs") of GSK plc (NYSE:GSK) between February 5, 2020 and August 14, 2022, both dates inclusive (the "Class Period"), of the important April 7, 2025 lead plaintiff deadline. SO WHAT: If you purchased GSK ADRs during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Read More
image for news ROSEN, A LEADING LAW FIRM, Encourages GSK plc Investors to Secure Counsel Before Important Deadline in Securities Class Action - GSK
GSK plc Sued for Securities Law Violations - Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights – GSK
GSK
Published: March 07, 2025 by: GlobeNewsWire
Sentiment: Neutral

NEW YORK, March 07, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in GSK plc ("GSK" or the "Company") (NYSE: GSK) of a class action securities lawsuit.

Read More
image for news GSK plc Sued for Securities Law Violations - Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights – GSK
Glaxo (GSK) Up 8% Since Last Earnings Report: Can It Continue?
GSK
Published: March 07, 2025 by: Zacks Investment Research
Sentiment: Positive

Glaxo (GSK) reported earnings 30 days ago. What's next for the stock?

Read More
image for news Glaxo (GSK) Up 8% Since Last Earnings Report: Can It Continue?
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in GSK plc of Class Action Lawsuit and Upcoming Deadlines - GSK
GSK
Published: March 07, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / March 7, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against GSK plc ("GSK" or the "Company") (NYSE:GSK). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.

Read More
image for news INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in GSK plc of Class Action Lawsuit and Upcoming Deadlines - GSK
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in GSK plc of Class Action Lawsuit and Upcoming Deadlines - GSK
GSK
Published: March 05, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / March 5, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against GSK plc ("GSK" or the "Company") (NYSE:GSK). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.

Read More
image for news INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in GSK plc of Class Action Lawsuit and Upcoming Deadlines - GSK
Lost Money on GSK plc (GSK)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
GSK
Published: March 04, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / March 4, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=133961&wire=1 or contact Joseph E. Levi, Esq.

Read More
image for news Lost Money on GSK plc (GSK)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages GSK plc Investors to Secure Counsel Before Important Deadline in Securities Class Action – GSK
GSK
Published: March 04, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / March 4, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Receipts ("ADRs") of GSK plc (NYSE:GSK) between February 5, 2020 and August 14, 2022, both dates inclusive (the "Class Period"), of the important April 7, 2025 lead plaintiff deadline. SO WHAT: If you purchased GSK ADRs during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Read More
image for news ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages GSK plc Investors to Secure Counsel Before Important Deadline in Securities Class Action – GSK
Shareholders that lost money on GSK plc(GSK) Urged to Join Class Action – Contact Levi & Korsinsky to Learn More
GSK
Published: March 04, 2025 by: GlobeNewsWire
Sentiment: Neutral

NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in GSK plc ("GSK" or the "Company") (NYSE: GSK) of a class action securities lawsuit.

Read More
image for news Shareholders that lost money on GSK plc(GSK) Urged to Join Class Action – Contact Levi & Korsinsky to Learn More
Contact Levi & Korsinsky by April 7, 2025 Deadline to Join Class Action Against GSK plc (GSK)
GSK
Published: March 04, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / March 4, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=133855&wire=1 or contact Joseph E. Levi, Esq.

Read More
image for news Contact Levi & Korsinsky by April 7, 2025 Deadline to Join Class Action Against GSK plc (GSK)
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 7, 2025 in GSK Lawsuit - GSK
GSK
Published: March 03, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / March 3, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=133593&wire=1 or contact Joseph E. Levi, Esq.

Read More
image for news Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 7, 2025 in GSK Lawsuit - GSK

About GSK plc (GSK)

  • IPO Date 1980-03-28
  • Website https://www.gsk.com
  • Industry Drug Manufacturers - General
  • CEO Emma Natasha Walmsley
  • Employees 68629

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.